JP2010500411A5 - - Google Patents

Download PDF

Info

Publication number
JP2010500411A5
JP2010500411A5 JP2009524659A JP2009524659A JP2010500411A5 JP 2010500411 A5 JP2010500411 A5 JP 2010500411A5 JP 2009524659 A JP2009524659 A JP 2009524659A JP 2009524659 A JP2009524659 A JP 2009524659A JP 2010500411 A5 JP2010500411 A5 JP 2010500411A5
Authority
JP
Japan
Prior art keywords
mixture
extrudate
solubilizer
therapeutic compound
heating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009524659A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010500411A (ja
JP5546860B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/017960 external-priority patent/WO2008021347A2/en
Publication of JP2010500411A publication Critical patent/JP2010500411A/ja
Publication of JP2010500411A5 publication Critical patent/JP2010500411A5/ja
Application granted granted Critical
Publication of JP5546860B2 publication Critical patent/JP5546860B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2009524659A 2006-08-16 2007-08-14 高結晶性治療化合物の固体分散体を製造するための方法 Expired - Fee Related JP5546860B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82255606P 2006-08-16 2006-08-16
US60/822,556 2006-08-16
PCT/US2007/017960 WO2008021347A2 (en) 2006-08-16 2007-08-14 Method for making solid dispersions of highly crystalline therapeutic compounds

Publications (3)

Publication Number Publication Date
JP2010500411A JP2010500411A (ja) 2010-01-07
JP2010500411A5 true JP2010500411A5 (enExample) 2010-09-24
JP5546860B2 JP5546860B2 (ja) 2014-07-09

Family

ID=38657762

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009524659A Expired - Fee Related JP5546860B2 (ja) 2006-08-16 2007-08-14 高結晶性治療化合物の固体分散体を製造するための方法

Country Status (16)

Country Link
US (2) US20100038816A1 (enExample)
EP (1) EP2054040B1 (enExample)
JP (1) JP5546860B2 (enExample)
KR (1) KR101462693B1 (enExample)
CN (1) CN101516339B (enExample)
AT (1) ATE503484T1 (enExample)
AU (1) AU2007284615B2 (enExample)
BR (1) BRPI0714963A2 (enExample)
CA (1) CA2660086C (enExample)
DE (1) DE602007013567D1 (enExample)
ES (1) ES2363725T3 (enExample)
MX (1) MX2009001636A (enExample)
PL (1) PL2054040T3 (enExample)
PT (1) PT2054040E (enExample)
RU (1) RU2454220C2 (enExample)
WO (1) WO2008021347A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
MX2010011962A (es) * 2008-04-30 2010-11-30 Novartis Ag Proceso continuo para hacer composiciones farmaceuticas.
EP2327706A1 (en) 2009-11-30 2011-06-01 Novartis AG Polymorphous forms III and IV of N-benzoyl-staurosporine
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CN102525879B (zh) * 2010-12-31 2015-01-21 正大天晴药业集团股份有限公司 制备阿瑞匹坦固体分散组合物的方法
HRP20200372T1 (hr) * 2014-03-25 2020-06-12 F. Hoffmann - La Roche Ag Postupci proizvodnje poloksamera za upotrebu u mediju za staničnu kulturu
CA2970717A1 (en) 2014-12-18 2016-06-23 Merck Sharp & Dohme Corp. (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
GB201502073D0 (en) * 2015-02-09 2015-03-25 Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd HDEG technology
EP3337454B1 (en) 2015-08-20 2018-12-26 Unilever Plc. Improved lactam solubility
EP3337448A1 (en) * 2015-08-20 2018-06-27 Unilever PLC, a company registered in England and Wales under company no. 41424 of Dispersed lactams
WO2017029104A1 (en) 2015-08-20 2017-02-23 Unilever Plc Process for the preparation of lactams from glyoxylic acid
WO2017029092A1 (en) 2015-08-20 2017-02-23 Unilever Plc Improved lactam solubility
TR201901410T4 (tr) 2015-08-20 2019-02-21 Unilever Nv Geliştirilmiş Laktam Çözünürlüğü
CN107920979A (zh) 2015-08-20 2018-04-17 荷兰联合利华有限公司 改善的内酰胺溶解度
CN108024939B (zh) 2015-08-20 2024-06-07 联合利华知识产权控股有限公司 包封的内酰胺
CA3018629A1 (en) * 2016-03-24 2017-09-28 Locate Therapeutics Limited Scaffolding material, methods and uses
US11510986B2 (en) * 2016-05-13 2022-11-29 Merck Patent Gmbh Hot melt extrusion composition using direct compressible excipient as plasticizer
WO2019152798A1 (en) 2018-02-01 2019-08-08 Corvus Pharmaceuticals, Inc. Pharmaceutical formulations
EP3520782A3 (en) * 2018-02-01 2019-11-13 Corvus Pharmaceuticals, Inc. Pharmaceutical formulations containing adenosine a2a receptor antagonists
CN113573712A (zh) 2019-02-18 2021-10-29 斯莱班克制药有限责任公司 尼洛替尼的药物组合物
CA3203975A1 (en) 2020-12-03 2022-06-09 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
CA3216359A1 (en) 2021-04-07 2022-10-13 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
CN114796149A (zh) * 2022-04-27 2022-07-29 苏州中化药品工业有限公司 一种高生物利用度的双醋瑞因胶囊剂及其制备方法
AU2024353375A1 (en) 2023-09-29 2026-04-09 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
IE80467B1 (en) 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
US5837714A (en) * 1997-03-03 1998-11-17 Sanofi Solid pharmaceutical dispersions
DE69811233T2 (de) 1997-10-27 2003-11-20 Merck Patent Gmbh Feste lösungen und dispersionen von eines schlecht wasserlöslichen wirkstoffes
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6593308B2 (en) * 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
US20020015730A1 (en) * 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
DE10013289A1 (de) * 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
PT1372611E (pt) * 2001-03-26 2006-08-31 Novartis Ag Composicao farmaceutica compreendendo uma estaurosporina francamente soluvel em agua, um tensioactivo et um polimero soluvel em agua
CN1255185C (zh) * 2001-05-03 2006-05-10 弗·哈夫曼-拉罗切有限公司 无定形甲磺酸奈非那韦的药物剂型
US20030212102A1 (en) * 2001-06-12 2003-11-13 Koretke Todd W Novel solid dispersion compositions
JP4644397B2 (ja) * 2001-09-05 2011-03-02 信越化学工業株式会社 難溶性薬物を含む医薬用固形製剤の製造方法
US6756381B2 (en) * 2002-02-21 2004-06-29 Supergen, Inc. Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereof
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
US8268352B2 (en) * 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US7230012B2 (en) * 2002-11-14 2007-06-12 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide
GB0315012D0 (en) * 2003-06-27 2003-07-30 Leuven K U Res & Dev Zeotiles
AR047938A1 (es) * 2003-08-25 2006-03-15 Combinatorx Inc Formulaciones, conjugados y combinaciones de farmacos para el tratamiento de neoplasmas
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
KR20060101762A (ko) * 2003-11-21 2006-09-26 쉐링 코포레이션 포스포디에스테라제 ｖ 억제제 제형
WO2005053727A2 (en) * 2003-11-29 2005-06-16 Sangstat Medical Corporation Pharmaceutical compositions for bioactive peptide agents
UA85871C2 (uk) * 2004-03-15 2009-03-10 Такеда Фармасьютікал Компані Лімітед Інгібітори дипептидилпептидази
US20060246109A1 (en) * 2005-04-29 2006-11-02 Hossainy Syed F Concentration gradient profiles for control of agent release rates from polymer matrices
US20050288481A1 (en) * 2004-04-30 2005-12-29 Desnoyer Jessica R Design of poly(ester amides) for the control of agent-release from polymeric compositions
RU2410098C2 (ru) * 2004-08-31 2011-01-27 Новартис Аг Применение мидостаурина для лечения желудочно-кишечных стромальных опухолей
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
JO2897B1 (en) * 2004-11-05 2015-09-15 نوفارتيس ايه جي Organic compounds
JP2008521878A (ja) * 2004-12-02 2008-06-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 非晶質アトルバスタチンの医薬組成物及びその製造のための方法
PT1962808E (pt) * 2005-12-14 2010-10-29 Hoffmann La Roche Formulação de precursor de fármaco para o hcv
DK2526933T3 (en) * 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
US8258137B2 (en) * 2008-01-29 2012-09-04 Katholieke Universiteit Leuven Process for release of biologically active species from mesoporous oxide systems
CN102413839A (zh) * 2009-03-06 2012-04-11 医学免疫有限责任公司 人源化抗cd19抗体制剂
TW201120037A (en) * 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
EP2327706A1 (en) * 2009-11-30 2011-06-01 Novartis AG Polymorphous forms III and IV of N-benzoyl-staurosporine
CA3007787C (en) * 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
EP2618846A1 (en) * 2010-09-24 2013-07-31 Mallinckrodt LLC Aptamer conjugates for targeting of therapeutic and/or diagnostic nanocarriers
US9295673B2 (en) * 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof

Similar Documents

Publication Publication Date Title
JP2010500411A5 (enExample)
JP5546860B2 (ja) 高結晶性治療化合物の固体分散体を製造するための方法
KR102803917B1 (ko) 루카파립의 고 용량 강도 정제
JP2019108366A (ja) Ｃｇｒｐ活性化合物の錠剤製剤
CN107529758A (zh) 固体分散体
CN1359294A (zh) 含有乙酰水杨酸和氯吡格雷硫酸氢盐的单位剂型形药物组合物
JP6276287B2 (ja) フェキソフェナジン高含有固形単位およびその製造法
US20080292702A1 (en) Solid Dispersion Comprising An Active Ingredient Having A Low Melting Point And Tablet For Oral Administration Comprising Same
TR201901792T4 (tr) Yeni (trimetoksifenilamino)pirimidinil formülasyonları.
JP2018516942A (ja) 生体利用率が改善された含プランルカスト固形製剤の組成物及びその製造方法
CN109730967B (zh) 一种硝苯地平固体分散体及其制备方法
WO2026077307A1 (zh) 神经活性类固醇固体分散体、固体分散体组合物及制备方法和应用、含有固体分散体的药物
Dzoagbe et al. Advances in Co-Processed Excipients: Multifunctional Platforms for Diverse Pharmaceutical Formulations.
JP6216408B2 (ja) 固体剤形で非常に難溶性の薬物を調製する方法
EP3250188B1 (en) Pharmaceutical composition comprising aprepitant and method for the preparation thereof
KR20000069356A (ko) 급속방출식 약물전달 제형
AU2016217658A1 (en) Method of producing a granulated composition
JP6235924B2 (ja) フェノフィブラートの固体分散体
Almotairy Formulation Development and Targeted Delivery for BCS II Drugs Using Hot Melt Extrusion Technology
Sarabu Application of Hot Melt Extrusion and 3D Printing Techniques in Development of Pharmaceutical Dosage Forms
DE202020005452U1 (de) Zusammensetzung, enthaltend natürliche lipophile Verbindungen
JP2017222728A (ja) フェノフィブラートの固体分散体